Swiss pharmaceutical company Novartis Pharma AG (SIX:NOVN) (NYSE:NVS) reported on Wednesday that twice-yearly Leqvio (inclisiran) has shown significant LDL-C reduction in a Phase III study involving patients who were at low or moderate risk of developing atherosclerotic cardiovascular disease (ASCVD) and not receiving lipid-lowering therapy.
The positive topline results of the V-MONO study add to the growing evidence supporting Leqvio's effectiveness in various ASCVD prevention settings. Novartis plans to present results from this trial at an upcoming medical meeting and share the data with regulatory agencies including the US Food and Drug Administration (FDA).
Novartis is also conducting other studies evaluating Leqvio's potential for primary and secondary ASCVD prevention.
Lilly expands manufacturing footprint in Ireland
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
Merck's GARDASIL 9 shows promise in preventing HPV infection in Japanese males
Pheon Therapeutics names new independent, non-executive director
Solu Therapeutics names new chief medical officer
Tyra Biosciences names new chief medical officer
Arecor reports positive Phase I Results for AT278 insulin at EASD 2024